Novartis considers eye care division IPO or spin-off

Aidan Gregory

January 25, 2017 11:00 am

Novartis_AP_230x150 — FILE - In this Dec. 13, 2007 file photo, the Novartis building in Basel, Switzlerland is shown. Drug maker Novartis AG on Monday, Jan. 4, 2010 said it plans to take over Alcon Inc. by paying $38.5 billion for the 77 percent stake it does not already own in a deal that would make it one of the biggest players in the global market for eye-care products. (AP Photo/Keystone/Georgios Kefalas, File) | GEORGIOS KEFALAS/ASSOCIATED PRESS

In a relatively quiet week for live equity deals, Novartis, one of Europe’s largest pharmaceutical companies, has said it is considering an IPO or spin-off of its eye care division, and a real estate investment trust announced the year’s first London IPO of significant size.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Switzerland Deutsche Bank JP Morgan Equity IPOs UBS Equity Bank of America Europe EMEA

AG

Aidan Gregory